These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17278089)

  • 1. Breast tumours following combined hormone replacement therapy express favourable prognostic factors.
    Borgquist S; Anagnostaki L; Jirström K; Landberg G; Manjer J
    Int J Cancer; 2007 May; 120(10):2202-7. PubMed ID: 17278089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
    Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
    Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy.
    Manjer J; Malina J; Berglund G; Bondeson L; Garne JP; Janzon L
    Int J Cancer; 2001 Jun; 92(6):919-22. PubMed ID: 11351317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability.
    Brändstedt J; Wangefjord S; Nodin B; Eberhard J; Jirström K; Manjer J
    BMC Cancer; 2014 May; 14():371. PubMed ID: 24885829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parity and age at first childbirth in relation to the risk of different breast cancer subgroups.
    Butt S; Borgquist S; Anagnostaki L; Landberg G; Manjer J
    Int J Cancer; 2009 Oct; 125(8):1926-34. PubMed ID: 19569233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer.
    Bièche I; Parfait B; Laurendeau I; Girault I; Vidaud M; Lidereau R
    Oncogene; 2001 Dec; 20(56):8109-15. PubMed ID: 11781824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthropometric factors in relation to different tumor biological subgroups of postmenopausal breast cancer.
    Borgquist S; Jirström K; Anagnostaki L; Manjer J; Landberg G
    Int J Cancer; 2009 Jan; 124(2):402-11. PubMed ID: 18798278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.
    Li CI; Malone KE; Porter PL; Weiss NS; Tang MT; Cushing-Haugen KL; Daling JR
    JAMA; 2003 Jun; 289(24):3254-63. PubMed ID: 12824206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin D1 overexpression associates with favourable prognostic factors in invasive breast carcinoma.
    El-Hafez AA; El Aaty Shawky A; Hasan B
    Cancer Biomark; 2012; 12(4):149-54. PubMed ID: 23568005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
    Ross RK; Paganini-Hill A; Wan PC; Pike MC
    J Natl Cancer Inst; 2000 Feb; 92(4):328-32. PubMed ID: 10675382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast.
    Hofseth LJ; Raafat AM; Osuch JR; Pathak DR; Slomski CA; Haslam SZ
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4559-65. PubMed ID: 10599719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk.
    Rebbeck TR; Troxel AB; Norman S; Bunin G; DeMichele A; Schinnar R; Berlin JA; Strom BL
    Am J Epidemiol; 2007 Dec; 166(12):1392-9. PubMed ID: 17827444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type and duration of exogenous hormone use affects breast cancer histology.
    Kumar AS; Cureton E; Shim V; Sakata T; Moore DH; Benz CC; Esserman LJ; Hwang ES
    Ann Surg Oncol; 2007 Feb; 14(2):695-703. PubMed ID: 17103262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intake of whole grain products and risk of breast cancer by hormone receptor status and histology among postmenopausal women.
    Egeberg R; Olsen A; Loft S; Christensen J; Johnsen NF; Overvad K; Tjønneland A
    Int J Cancer; 2009 Feb; 124(3):745-50. PubMed ID: 19004010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
    Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
    Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for HR- and HER2-defined breast cancer in Slovenian postmenopausal women.
    Cerne JZ; Ferk P; Frkovic-Grazio S; Leskosek B; Gersak K
    Climacteric; 2012 Feb; 15(1):68-74. PubMed ID: 22132797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors.
    Borgquist S; Djerbi S; Pontén F; Anagnostaki L; Goldman M; Gaber A; Manjer J; Landberg G; Jirström K
    Int J Cancer; 2008 Sep; 123(5):1146-53. PubMed ID: 18528862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe.
    Stahlberg C; Pedersen AT; Lynge E; Andersen ZJ; Keiding N; Hundrup YA; Obel EB; Ottesen B
    Int J Cancer; 2004 May; 109(5):721-7. PubMed ID: 14999781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.